AU2003298611A1 - Mixed lineage kinase modulators - Google Patents

Mixed lineage kinase modulators

Info

Publication number
AU2003298611A1
AU2003298611A1 AU2003298611A AU2003298611A AU2003298611A1 AU 2003298611 A1 AU2003298611 A1 AU 2003298611A1 AU 2003298611 A AU2003298611 A AU 2003298611A AU 2003298611 A AU2003298611 A AU 2003298611A AU 2003298611 A1 AU2003298611 A1 AU 2003298611A1
Authority
AU
Australia
Prior art keywords
mixed lineage
kinase modulators
lineage kinase
modulators
mixed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003298611A
Inventor
Arindam Chatterjee
Theodore Junior Goodson
Mary Margaret Mader
John Eldon Toth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2003298611A1 publication Critical patent/AU2003298611A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
AU2003298611A 2002-11-21 2003-11-12 Mixed lineage kinase modulators Abandoned AU2003298611A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42832202P 2002-11-21 2002-11-21
US60/428,322 2002-11-21
PCT/US2003/035036 WO2004048383A1 (en) 2002-11-21 2003-11-12 Mixed lineage kinase modulators

Publications (1)

Publication Number Publication Date
AU2003298611A1 true AU2003298611A1 (en) 2004-06-18

Family

ID=32393381

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003298611A Abandoned AU2003298611A1 (en) 2002-11-21 2003-11-12 Mixed lineage kinase modulators

Country Status (5)

Country Link
EP (1) EP1567528A1 (en)
JP (1) JP2006522735A (en)
AU (1) AU2003298611A1 (en)
CA (1) CA2506799A1 (en)
WO (1) WO2004048383A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
CR9465A (en) * 2005-03-25 2008-06-19 Surface Logix Inc PHARMACOCINETICALLY IMPROVED COMPOUNDS
US7872020B2 (en) * 2005-07-22 2011-01-18 Eli Lilly And Company TGF-β inhibitors
US7919519B2 (en) 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
EP1965807A4 (en) * 2005-11-23 2010-10-27 Epix Delaware Inc S1p receptor modulating compounds and use thereof
AU2007227274A1 (en) 2006-03-21 2007-09-27 Epix Delaware, Inc. S1P receptor modulating compounds
LT3357911T (en) 2006-06-26 2022-08-10 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
EP2364976B1 (en) * 2007-03-21 2014-10-08 EPIX Pharmaceuticals, Inc. S1P receptor modulating compounds and use thereof
MX2010002885A (en) 2007-09-20 2010-04-01 Amgen Inc S1p receptor modulating compounds and use thereof.
DE102009001438A1 (en) 2009-03-10 2010-09-16 Bayer Schering Pharma Aktiengesellschaft New carbonylamino-substituted anilino-pyrimidine compounds are tyrosine kinase-2 inhibitors, useful for treating diseases associated with inflammatory conditions e.g. bronchitis, rheumatoid arthritis, psoriasis and Guillain Barre syndrome
DE102009015070A1 (en) 2009-03-30 2010-10-14 Bayer Schering Pharma Aktiengesellschaft New phenyl-pyrimidin-2-yl-amine compounds are tyrosine kinase 2 inhibitors useful for treating e.g. rheumatoid arthritis, Crohn's disease, asthma, multiple sclerosis, adult respiratory distress syndrome, allergic alveolitis and uveitis
CN103717214A (en) 2011-06-06 2014-04-09 阿克比治疗有限公司 Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (en) 2011-06-06 2018-03-17
LT3007695T (en) 2013-06-13 2024-03-25 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
TW201632504A (en) 2015-01-23 2016-09-16 阿克比治療有限公司 Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
ES2918924T3 (en) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc TGF-beta inhibitors
CR20170450A (en) 2015-04-01 2018-04-03 Akebia Therapeutics Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF THE ANEMIA
CN107663206B (en) 2016-07-29 2021-06-18 上海璎黎药业有限公司 Nitrogen-containing aromatic heterocyclic compound, preparation method thereof, pharmaceutical composition and application thereof
CN110066276B (en) 2018-01-24 2020-09-18 上海璎黎药业有限公司 Aromatic heterocyclic compound, intermediate thereof, preparation method, pharmaceutical composition and application
CN110066277B (en) 2018-01-24 2021-07-23 上海璎黎药业有限公司 Aromatic heterocyclic substituted olefin compound, preparation method, pharmaceutical composition and application thereof
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
DE60221392T2 (en) * 2001-05-24 2008-04-17 Eli Lilly And Co., Indianapolis NEW PYROL DERIVATIVES AS PHARMACEUTICAL AGENTS

Also Published As

Publication number Publication date
EP1567528A1 (en) 2005-08-31
WO2004048383A1 (en) 2004-06-10
CA2506799A1 (en) 2004-06-10
JP2006522735A (en) 2006-10-05

Similar Documents

Publication Publication Date Title
AU2003298611A1 (en) Mixed lineage kinase modulators
AU2003249369A1 (en) Certain amino-substituted monocycles as kinase modulators
AU2003245773A1 (en) Vanilloid receptor modulators
AU2003253535A1 (en) N-4-piperidinyl compounds as ccr5 modulators
AU2003245669A1 (en) Certain aromatic monocycles as kinase modulators
AU2002345661A1 (en) Display devices with organic-metal mixed layer
AU2003233704A1 (en) Electro-optic modulators
AU2002951247A0 (en) Compounds that interact with kinases
AU2003225031A1 (en) Eptfe-reinforced perfluoroelastomers
AU2003247842A1 (en) Screen sharing
AU2003253880A1 (en) Novel kinases
AU2003223405A1 (en) Technique for distributing sotware background
AU2003301654A1 (en) Stabilized composition
AU2003241601A1 (en) Anilino liver x-receptor modulators
AU2003272552A1 (en) Aromatic liver x-receptor modulators
AU2003221577A1 (en) Entitlements administration
AU2003226487A1 (en) Formulation
AU2003218991A1 (en) Colouring agents
AU2003205970A1 (en) Software distribution
AU2003228614A1 (en) Lxr modulators
AU2003217110A1 (en) Novel formulation
AU2003206210A1 (en) Educational block set
EP1581309A4 (en) Kinase modulators
AU2002367757A1 (en) Mixer
AU2003303520A1 (en) Irs modulators

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase